A clinical formulation indicated for Autoimmune Care. Targeted immune-modulating properties facilitate the suppression of overactive responses and reduce related systemic inflammation.
Designed to support autoimmune remission by addressing immune cell overactivity to alleviate systemic inflammation and mitigate the risk of organ transplant rejection effectively.
Mechanism of Action
Azathioprine is converted into compounds that mimic the building blocks of DNA. It incorporates itself into the genetic material of rapidly dividing immune cells, disrupting their replication and suppressing the body's overactive immune response.
Route of Administration
Oral
Onset Time
6–12 weeks
Duration
12–24 hours
Contraindications
Pregnancy, Hypersensitivity to azathioprine, Previous treatment with alkylating agents, Severe infection
Severe Adverse Events
Bone marrow suppression, Liver toxicity, Pancreatitis, Increased cancer risk (Lymphoma), Severe skin reactions
Common Side Effects
Mild nausea, Loss of appetite
Uncommon Side Effects
Vomiting, Fatigue, Joint pain, Increased risk of infection, Skin rash
Drug Interactions
Allopurinol, Febuxostat, Warfarin, ACE inhibitors, Sulfasalazine, Live vaccines
Information for Azathioprine is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
